Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico

 April 15, 2026

BioSpace

After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.

M&A / DealsRead full story

Post navigation

Parkinson’s charity partners Biognosys on biomarker project →
← Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com